⌕
Adaptive Biotechnologies · ADPT · Nasdaq
Tenet 42 · Weak
Compare
$27.87−4.03%At closeTenet 42 · Weak
$27.87−1.17 (−4.03%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Adaptive Biotechnologies (ADPT) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~15.7%/yr (FY21→FY25), net margin −21.5%. Worth your attention in FY25: Share count (+8.1%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲54.8%
277.0
FY21→FY25CAGR +15.7%/yr
Net income ($M)▲62.7%
−59.5
FY21→FY25CAGR —
Free cash flow ($M)▲50.5%
−48.9
FY21→FY25CAGR —
Diluted EPS▲63.9%
−0.39
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+8.1%

140.4mn → 151.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$3.0M

−19.2% YoY in FY25 · 1.1% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)277.0Revenue−71.4COGS205.6Gross profit−93.8R&D−72.7SG&A−57.1Op income−2.3Tax & other−59.5Net income

-21¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
806040200%sector median net margin ~4%FY21FY25

Over this window: gross 68.1% → 74.2%. Net margin -21.5% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
298,010.0276,976.0178,957.0170,276.0185,308.0154,344.0▲54.8%+15.7%
Cost of revenue
77,030.071,359.072,080.075,553.057,909.049,301.0▼1.0%+9.7%
Gross profit
220,980.0205,617.0106,877.094,723.0127,399.0105,043.0▲92.4%+18.3%
Research & development
83,177.093,769.0102,953.0122,117.0141,756.0142,343.0▼8.9%−9.9%
Selling, general & admin
80,173.072,701.072,806.083,934.088,527.074,502.0▼0.1%−0.6%
Total operating expenses
269,186.0262,740.0269,426.0321,758.0327,585.0314,009.0▼2.5%−4.4%
Operating incomefeeds ROC rank
−48,206.0−57,123.0−162,549.0−227,035.0−200,186.0−208,966.0▲64.9%—
Other income, net
−22,523.0−2,334.02,954.01,731.0−182.01,668.0——
Pretax income
−70,729.0−59,457.0−159,595.0−225,304.0−200,368.0−207,298.0▲62.7%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−70,729.0−59,457.0−159,595.0−225,304.0−200,368.0−207,298.0▲62.7%—
Per share
Diluted EPSbuyback-sensitive
−0.44−0.39−1.08−1.56−1.40−1.48▲63.9%—
Diluted shares (mn)
186.88151.72147.10144.38142.52140.35▲3.1%+2.0%
Margins
Gross margin66th pct in Healthcare
74.2%74.2%59.7%55.6%68.7%68.1%▲14.5pp+6.2pp
Operating margin
−16.2%−20.6%−90.8%−133.3%−108.0%−135.4%▲70.2pp+114.8pp
Net margin21st pct in Healthcare
−23.7%−21.5%−89.2%−132.3%−108.1%−134.3%▲67.7pp+112.8pp
† TTM = trailing four quarters through 2026-09-30.
FY17 – FY20 · 4 more years
Unlock the full history →
4 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Adaptive Biotechnologies' revenue last fiscal year?

Adaptive Biotechnologies reported revenue of $277.0M in fiscal 2025, up 54.8% from fiscal 2024.

What was Adaptive Biotechnologies' net income?

Adaptive Biotechnologies reported net income of −$59.5M in fiscal 2025, a net margin of −21.5%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.